Login to Your Account



EMA to Start Requiring Genetic Variability Data for Approval

By Nuala Moran
Staff Writer

Wednesday, February 15, 2012
LONDON – The European Medicines Agency (EMA) has published guidelines describing how it wants to see the consequences of genetic variability between patients integrated into the investigation of pharmacokinetics of drugs in development.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription